New TB vaccines enter human testing – could they prevent a global killer?
NCT ID NCT05537038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested two experimental vaccines (BNT164a1 and BNT164b1) against tuberculosis in 120 healthy adults who had never been exposed to TB or received the BCG vaccine. The main goal was to check safety and find the best dose. Participants received three doses of either a vaccine or a placebo, and researchers monitored side effects and immune responses for several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
-
emovis GmbH
Berlin, 10629, Germany